ALBERTO SANCHEZ ESPINOSA

Dr. ALBERTO SANCHEZ ESPINOSA

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AEALBERTO SANCHEZ ESPINOSA
ALBERTO SANCHEZ ESPINOSA
JGJosé García-Rodríguez
José García-Rodríguez
VAVIRGINIA ALONSO AGUIRRE
VIRGINIA ALONSO AGUIRRE
JAJesús María Acosta-Ortega
Jesús María Acosta-Ortega
PCPablo Conesa-Zamora
Pablo Conesa-Zamora
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
Background/Objectives: Breast cancer is the most prevalent cancer in adult women. Currently, new therapies and protein determinations with prognostic value are under development. Fascin (encoded by the FSCN1 gene) is an actin-binding protein that is critical for the development of cytoplasmic projections that are essential for tumor invasion. DNA topoisomerase 2-alpha (TOP2A) is a nuclear protein crucial for ATP-dependent breakage, passage, and rejoining of double-stranded DNA and cell division. Both proteins are associated with higher proliferation rates and worse prognosis in breast cancer and together can provide comprehensive information on prognosis and treatment response. Methods: We simultaneously assessed fascin expression and TOP2A/CEP17 DNA copy number ratios in various histological and molecular subtypes. Additionally, these markers were analyzed along with previously established diagnostic markers and other relevant clinical data. Results: Our series included 265 patients, four of whom were male, and all of which were diagnosed with breast carcinoma. Of the 265 patients initially included, sufficient material for analysis was available for 175 cases, as some samples were excluded because of insufficient tissue quantity, poor preservation, or lack of hybridization in certain assays. Immunohistochemical (IHC) expression of fascin, both in its aggregated form and by category, showed no association with the TOP2A gene alteration ratio. Fascin expression was significantly associated with histological subtype (p < 0.001), molecular subtype (p < 0.001), hormone receptor (HR) (p < 0.001), BCL2 (p = 0.003), Ki67 (p = 0.002), and histological grade (p < 0.001). TOP2A was significantly associated with molecular subtype (p = 0.041), Ki67 (p = 0.048), and histological grade (p = 0.033). In our study, molecular subtype (p = 0.037) emerged as an independent variable for the complete histological response to neoadjuvant treatment. Multivariate analysis linked pathological stage (p = 0.002) and estrogen receptor (ER) expression (p = 0.004) to overall survival (OS) and disease-free survival (DFS). Conclusions: No statistical relationship was evident between fascin expression (IHC) and the TOP2A copy ratio. The results of this study suggested that the mechanisms of increased cell proliferation associated with alterations in fascin and TOP2A are independent.

7 November 2026 in Biology
Verified
Journal Article
Open access
PDF file
VAVirginia Alonso-Aguirre
Virginia Alonso-Aguirre
AEALBERTO SANCHEZ ESPINOSA
ALBERTO SANCHEZ ESPINOSA
JGJosé García-Rodríguez
José García-Rodríguez
ASAntonio David Lázaro Sánchez
Antonio David Lázaro Sánchez
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
Risk stratification in localised prostate cancer still relies mainly on clinical, pathological and genomic variables, whereas readily deployable tissue protein biomarkers remain insufficiently validated, particularly in patients treated with radiotherapy. This narrative review examines periostin (POSTN), mitogen-activated protein kinase 8 interacting protein 2 (MAPK8IP2/JIP2), cell division cycle-associated protein 3 (CDCA3) and non-SMC condensin II complex subunit G2 (NCAPG2) as illustrative candidates within a hypothesis-generating framework of potentially complementary biological processes. The review links the available evidence on these candidates to testable radiobiological hypotheses and specific experimental and clinical validation strategies. We searched PubMed on 25 October 2026 for publications dated from 1 January 2021 through 14 July 2026. We also included selected earlier publications. POSTN had the relatively strongest prostate-cancer tissue-level rationale, with stromal expression associated with adverse features and recurrence-related or metastatic biology. MAPK8IP2/JIP2 was associated with stress signalling, androgen-receptor-related states, and adverse features, but the evidence was mainly retrospective, transcriptomic, and experimental. CDCA3 was linked to cell-cycle and checkpoint regulation, whereas NCAPG2 was associated with chromosome organisation, malignancy, and STAT3/c-MYC-related stemness. However, no study identified in the literature reviewed demonstrated radiotherapy-specific predictive value, fractionation sensitivity, or androgen-deprivation benefit for any candidate. Future studies should use standardised compartment-specific immunohistochemistry, spatial assessment, patient-level model development, independent validation, comparison with clinical and genomic classifiers, and prespecified biomarker-by-treatment interaction analyses.